138499-08-8

Basic information

• Product Name: (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE
• Synonyms: (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE;Carbonic Acid 2,5-Dioxopyrrolidin-1-yl (S)-Tetrahydrofuran-3-yl Ester;1-[[[[(3S)-Tetrahydro-3-furanyl]oxy]carbonyl]oxy]-2,5-pyrrolidinedione;3(S)-Hydroxy Tetrahydrofuran, N-HydroxysuccinaMidylcarbonate;(3S)-TetrahydrofuranylsuccinMidyl-carbonate;(S)-2,5-dioxopyrrolidin-1-yl (tetrahydrofuran-3-yl) carbonate
• CAS NO: 138499-08-8
• Molecular Formula: C₉H₁₁NO₆
• Molecular Weight: 229.05
• Product Categories: Miscellaneous Reagents
• Mol File: 138499-08-8.mol

Chemical Properties

• Melting Point: 114-117°C
• Boiling Point: 338.736 °C at 760 mmHg
• Flash Point: 158.662 °C
• Appearance: Off-white solid
• Density: 1.457 g/cm³
• Vapor Pressure: 9.63E-05mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate, Ether, Methanol
• CAS DataBase Reference: (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE(138499-08-8)
• EPA Substance Registry System: (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE(138499-08-8)

Safety Data

• Hazardous Substances Data: 138499-08-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE is used as a synthetic building block for the creation of various organic compounds. Its unique structure allows it to be a valuable intermediate in the synthesis of complex molecules, particularly in the pharmaceutical and chemical industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE is used as a key component in the development of new drugs. Its ability to form complex molecular structures makes it an essential tool in the design and synthesis of novel therapeutic agents.
Used in Chemical Industry:
(3S)-TETRAHYDROFURANYLSUCCINIMIDYL-CARBONATE is also utilized in the chemical industry for the production of specialty chemicals and materials. Its versatility in organic synthesis allows for the creation of a wide range of products, from advanced materials to fine chemicals.

InChI:InChI=1/C9H11NO6/c11-7-1-2-8(12)10(7)16-9(13)15-6-3-4-14-5-6/h6H,1-5H2/t6-/m0/s1

Upstream product

• 74124-79-1 di(succinimido) carbonate 
• 86087-23-2 (S)-3-hydroxytetyrahydrofurane 
• 75-44-5 phosgene 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 

Downstream Products

• 160231-69-6 4-nitro-N-((2R(syn),3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutylbenzenesulfonamide 
• 1259010-12-2 (S)-tetrahydrofuran-3-yl 3-(2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)azetidine-1-carboxylate 
• 1169870-26-1 C₂₅H₃₅N₃O₅S 
• 1601490-32-7 (S)-tetrahydrofuran-3-yl ((2S,3R)-4-((R)-7-fluoro-4-isopropyl-1,1-dioxido-4,5-dihydrobenzo[1,2-f]thiazepin-2(3H)-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 1601490-36-1 (S)-tetrahydrofuran-3-yl ((2S,3R)-4-((S)-7-fluoro-4-isopropyl-1,1-dioxido-4,5-dihydrobenzo[1,2-f]thiazepin-2(3H)-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 1601490-34-9 (S)-tetrahydrofuran-3-yl ((2S,3R)-4-((R)-4-(4-fluorophenyl)-1,1-dioxido-4,5-dihydrobenzo[1,2-f]thiazepin-2(3H)-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 1601490-33-8 (S)-tetrahydrofuran-3-yl ((2S,3R)-4-((R)-4-(tert-butyl)-7-fluoro-1,1-dioxido-4,5-dihydrobenzo[1,2-f]thiazepin-2(3H)-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 1601490-37-2 (S)-tetrahydrofuran-3-yl ((2S,3R)-4-((S)-4-(tert-butyl)-7-fluoro-1,1-dioxido-4,5-dihydrobenzo[1,2-f]thiazepin-2(3H)-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 161814-49-9 amprenavir 
• 478697-33-5 C₂₉H₃₇N₃O₆S 
• 1217206-83-1 C₂₉H₃₉N₃O₅S 

Relevant articles and documents

COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER

The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve d

OXAZEPINE DERIVATIVES HAVING TNAP INHIBITORY ACTIVITY

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

Lissencephaly therapeutic agent

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR and SAQUINAVIR

Disclosed herein is a novel route of synthesis of syn azide epoxide of formula 5, which is used as a common intermediate for asymmetric synthesis of HIV protease inhibitors such as Amprenavir, Fosamprenavir, Saquinavir and formal synthesis of Darunavir an

A PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE THE SYNTHESIS OF AMPRENAVIR and SAQUINAVIR

Disclosed herein is a novel route of synthesis of syn azide epoxide of formu 5, which is used as a common intermdeiate for asymmetric synthesis of HIV protease inhibitors such as Amprenavir, Fosamprenavir, Saquinavir and formal synthesis of Darunavir and

PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES

The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparat

LISSENCEPHALY THERAPEUTIC AGENT

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

Enantioselective synthesis of HIV protease inhibitor amprenavir via Co-catalyzed HKR of 2-(1-azido-2-phenylethyl)oxirane

A short and efficient enantioselective synthesis of the HIV protease inhibitor amprenavir 1 (99% ee) as well as a formal synthesis of saquinavir 3 have been achieved in high enantiomeric purity starting from commercially available materials. Our strategy mainly comprises a Co-catalyzed two-stereocentred hydrolytic kinetic resolution (HKR) of racemic 2-(1-azido-2-phenylethyl)oxirane as the chirality inducing step. Also presented is a concise synthesis of (S)-3-hydroxytetrahydrofuran 4, the key structural feature, in high enantiomeric purity (98% ee).

PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES

The present invention relates to fosamprenavir calcium (la) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]- 1-benzyl-2-(phosphonooxy)propyl carbamate (lb), and its process for prepar

METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS

Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.